Neutropenia News and Research

RSS

Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils, the most important type of white blood cell, in the blood.

Zevalin safe and effective for non-Hogdkin's lymphoma patients

According to a University of Pittsburgh Medical Center (UPMC) study, patients with advanced non-Hodgkin's lymphoma (NHL) previously treated with chemotherapy and adult stem cell transplantation can safely tolerate Zevalin (ibritumomab tiuxetan), a radiolabeled monoclonal antibody that targets radiation directly to a tumor.

17 May 2005

Breast cancer chemotherapy regimen associated with life-threatening complications

The chemotherapy regimen of doxorubicin plus docetaxel, used to treat breast cancer in a clinical trial, was associated with an increased risk of serious complications, resulting in the premature termination of the trial, according to a study in the May 18 issue of JAMA.

17 May 2005

SU11248 drug show promise against neuroendocrine tumors-stubborn cancers that respond poorly to chemotherapy

A unique, targeted anti-cancer drug appears to show promise against neuroendocrine tumors-stubborn cancers that have traditionally responded poorly to chemotherapy, according to research findings announced at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO).

17 May 2005

Process for disposal of dying neutrophils actively linked to neutrophil production

New research identifies a critical inhibitory step that is a key component of the feedback circuit regulating the balance between neutrophil production and destruction.

23 Mar 2005

How does the body keep the number of neutrophils produced constant in the blood?

Every day, the human body manufactures and destroys about 100 billion neutrophils- the most common type of white blood cell and one of the most highly-produced cells. Neutrophils live about eight hours, are bacteria-eaters and are a key component of the immune system. Without them, the body can be subject to life-threatening infection.

23 Mar 2005

Study finds new method can improve chemo survival

Seeking to find a way to lessen patients’ vulnerability to deadly infections following chemotherapy, researchers at the Stanford University School of Medicine have figured out a way to boost the immune function in animals following such treatments.

21 Dec 2004

Revlimid clinical data in newly diagnosed multiple myeloma presented

Celgene Corporation announced today that data evaluating clinical results on Revlimid (lenalidomide) as a new therapeutic approach for patients with newly diagnosed multiple myeloma (MM) was presented at the American Society of Hematology 46th Annual Meeting in San Diego.

7 Dec 2004

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Modern research is delving deep into the human genome to find the answers to medical mysteries and, hopefully, cures for the most deadly diseases. According to four new studies presented during the 46th Annual Meeting of the American Society of Hematology

5 Dec 2004

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

At the 46th Annual Meeting of the American Society of Hematology (ASH) preliminary data were presented from a phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia (MDS).

5 Dec 2004

Phase 3 results of Genasense plus Dexamethasone in patients with advanced multiple myeloma

Genta Incorporated announced that results from the Company's randomized Phase 3 clinical trial of Genasense(R) (oblimersen sodium) Injection in patients with relapsed or refractory multiple myeloma were presented today at the annual meeting of the American Society of Hematology (ASH) in San Diego, CA.

4 Dec 2004

European approval for Taxotere (docetaxel) in prostate cancer

Aventis, part of the sanofi-aventis Group announced today that the European Commission has approved Taxotere (docetaxel) Injection Concentrate for use in combination with prednisone as a treatment for men with androgen-independent (hormone- refractory) metastatic prostate cancer.

4 Nov 2004

Half of patients with aggressive non-Hodgkin's lymphoma fail to receive the recommended dose and schedule of chemotherapy

Approximately half of patients with aggressive non-Hodgkin's lymphoma (NHL) fail to receive the recommended dose and schedule of chemotherapy, reducing their chances for remission or cure.

20 Sep 2004

Alimta receives positive endorsement for lung cancer approval from FDA Advisory Committee

Eli Lilly and Company have announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration positively endorsed Alimta® (pemetrexed), an antifolate, for accelerated approval in the second-line treatment of non-small cell lung cancer.

29 Jul 2004

Investigational drug Abraxane is active and well tolerated in women with metastatic breast cancer

Investigational drug Abraxane™ (albumin nanoparticle paclitaxel), administered weekly without steroid premedication, is active and well tolerated in women with metastatic breast cancer whose disease had progressed while they were treated with paclitaxel (Taxol®) and/or docetaxel (Taxotere®).

15 Jun 2004

Chemotherapy regimen more effective and more toxic in Japanese patients than in American patients

A chemotherapy regimen commonly used to treat non-small cell lung cancer is both more effective and more toxic in Japanese patients than in American patients, researchers reported Saturday at the annual meeting of the American Society of Clinical Oncologists.

7 Jun 2004

Herceptin shows real promise in treatment of HER-2 positive breast disease

According to a study conducted at The University of Texas M. D. Anderson Cancer Center, more than twice as many women with early stage, HER-2 positive breast disease who received Herceptin as part of their pre-surgery chemotherapy had their tumors completely disappear compared to like patients who received only chemotherapy.

7 Jun 2004

Treatment helps 26% of black Americans with chronic hepatitis C

Twenty-six percent (26%) of black Americans (BA) with chronic hepatitis C who received treatment with Pegasys plus Copegus (peginterferon alfa-2a plus ribavirin) achieved a sustained virological response (SVR), according to study results published in the June 2004 issue of Hepatology.

1 Jun 2004

New study challenges current thinking about varied response to hepatitis C treatment in different racial groups

Results of a new study published in the current issue of the New England Journal of Medicine show that in patients who have chronic hepatitis C, genotype 1 -- the most common form of the disease and difficult to treat successfully -- non-Hispanic whites achieved one of the highest response rates reported to date, but response rates in African Americans were significantly lower.

27 May 2004

Neutropenia News and Research

Further Reading

Zevalin safe and effective for non-Hogdkin's lymphoma patients

Breast cancer chemotherapy regimen associated with life-threatening complications

SU11248 drug show promise against neuroendocrine tumors-stubborn cancers that respond poorly to chemotherapy

Process for disposal of dying neutrophils actively linked to neutrophil production

How does the body keep the number of neutrophils produced constant in the blood?

Study finds new method can improve chemo survival

Revlimid clinical data in newly diagnosed multiple myeloma presented

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

Phase 3 results of Genasense plus Dexamethasone in patients with advanced multiple myeloma

European approval for Taxotere (docetaxel) in prostate cancer

Half of patients with aggressive non-Hodgkin's lymphoma fail to receive the recommended dose and schedule of chemotherapy

Alimta receives positive endorsement for lung cancer approval from FDA Advisory Committee

Investigational drug Abraxane is active and well tolerated in women with metastatic breast cancer

Chemotherapy regimen more effective and more toxic in Japanese patients than in American patients

Herceptin shows real promise in treatment of HER-2 positive breast disease

Treatment helps 26% of black Americans with chronic hepatitis C

New study challenges current thinking about varied response to hepatitis C treatment in different racial groups

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News